Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Receivables - Net (2021 - 2023)

Historic Receivables - Net for Inhibikase Therapeutics (IKT) over the last 3 years, with Q2 2023 value amounting to $79604.0.

  • Inhibikase Therapeutics' Receivables - Net rose 111495.73% to $79604.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $79604.0, marking a year-over-year increase of 111495.73%. This contributed to the annual value of $39881.0 for FY2022, which is 6379.1% down from last year.
  • Per Inhibikase Therapeutics' latest filing, its Receivables - Net stood at $79604.0 for Q2 2023, which was up 111495.73% from $64521.0 recorded in Q1 2023.
  • Inhibikase Therapeutics' Receivables - Net's 5-year high stood at $110141.0 during Q4 2021, with a 5-year trough of $6552.0 in Q2 2022.
  • For the 3-year period, Inhibikase Therapeutics' Receivables - Net averaged around $51788.1, with its median value being $47976.0 (2022).
  • As far as peak fluctuations go, Inhibikase Therapeutics' Receivables - Net crashed by 6379.1% in 2022, and later surged by 111495.73% in 2023.
  • Quarter analysis of 3 years shows Inhibikase Therapeutics' Receivables - Net stood at $110141.0 in 2021, then plummeted by 63.79% to $39881.0 in 2022, then surged by 99.6% to $79604.0 in 2023.
  • Its last three reported values are $79604.0 in Q2 2023, $64521.0 for Q1 2023, and $39881.0 during Q4 2022.